BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 27680710)

  • 1. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Mian I; Milton DR; Shah N; Nieto Y; Popat UR; Kebriaei P; Parmar S; Oran B; Shah JJ; Manasanch EE; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2016 Dec; 122(24):3831-3837. PubMed ID: 27680710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
    McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
    J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
    Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
    N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommend maintenance therapy with lenalidomide in multiple myeloma.
    Manasanch EE
    Semin Oncol; 2016 Dec; 43(6):712-713. PubMed ID: 28061994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
    Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
    Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
    Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
    Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
    Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
    Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
    Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
    Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
    Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
    Alsina M; Becker PS; Zhong X; Adams A; Hari P; Rowley S; Stadtmauer EA; Vesole DH; Logan B; Weisdorf D; Qazilbash M; Popplewell LL; McClune B; Bensinger W; Riches M; Giralt SA; Pasquini MC;
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1183-9. PubMed ID: 24769014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide after stem-cell transplantation for multiple myeloma.
    McCarthy PL; Owzar K; Hofmeister CC; Hurd DD; Hassoun H; Richardson PG; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R; Moreb JS; Callander NS; Van Besien K; Gentile T; Isola L; Maziarz RT; Gabriel DA; Bashey A; Landau H; Martin T; Qazilbash MH; Levitan D; McClune B; Schlossman R; Hars V; Postiglione J; Jiang C; Bennett E; Barry S; Bressler L; Kelly M; Seiler M; Rosenbaum C; Hari P; Pasquini MC; Horowitz MM; Shea TC; Devine SM; Anderson KC; Linker C
    N Engl J Med; 2012 May; 366(19):1770-81. PubMed ID: 22571201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
    Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
    Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.